Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 201–300 of 1,000
de Ridder, J., Uren, A., Kool, J., Reinders, M., & Wessels, L. (2006) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0020166 · Cited by 115
“Specifically, it is suggested that murine leukemia virus (MLV) favors integration near transcription start sites (TSSs) due to local recognition of genomic features [14,15].”
BackgroundMLV integration site selection is driven by strong enhancers and active promoters
LaFave, M. C., Varshney, G. K., Gildea, D. E., Wolfsberg, T. G., Baxevanis, A. D., & Burgess, S. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1399 · Cited by 114
“The K562 integration profile in this region serves as a representative example of the overall integration pattern we observed genome-wide and is consistent with previous observations (10): in both cell lines, integrations were typically enriched near TSS and showed non-random intergenic patterns.”
ResultSelf-citationStem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
Wu, C., & Dunbar, C. E. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0159-1 · Cited by 114
“, 903 MLV integrations and 379 HIV-1 integrations were mapped after transduction and short-term culture of a human cell line, demonstrating that MLV retroviruses integrated near the start of transcriptional units whereas HIV-1 was again shown to preferentially integrated anywhere within the transcriptional unit, but n…”
BackgroundTiteux, M., Pendaries, V., Zanta-Boussif, M. A., Décha, A., Pironon, N., Tonasso, L., Mejia, J. E., Brice, A., Danos, O., & Hovnanian, A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.91 · Cited by 111
Chen, W. V., Delrow, J. J., Corrin, P. D., Frazier, J. P., & Soriano, P. M. (2004) · Nature Genetics · doi:10.1038/ng1306 · Cited by 115
“This may be attributable to preference of retrovirally mediated insertions in transcriptional start region”
Backgroundβ-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., Ruiz de Assin, R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 107
“Comparisons were made between the patterns of the vector integration in the transduced BM CD34 + cells after a brief in vitro expansion versus after engraftment in NSG mice to look for evidence of preferential in vivo selection of clones containing inte-grants near cancer-associated genes (44) or transcriptional start…”
InfluentialRetroviral Integrase Proteins and HIV-1 DNA Integration
Krishnan, L., & Engelman, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.397760 · Cited by 97
“Moloney murine leukemia virus, a gammaretrovirus, also favors genes but, by contrast to HIV-1, favors promoters over internal regions (80).”
BackgroundBeard, B. C., Trobridge, G. D., Ironside, C., McCune, J. S., Adair, J. E., & Kiem, H.-P. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40767 · Cited by 110
Hsu, C., Jones, S. A., Cohen, C. J., Zheng, Z., Kerstann, K., Zhou, J., Robbins, P. F., Peng, P. D., Shen, X., Gomes, T. J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-029173 · Cited by 110
“MLV-based vectors, which were used in this study, increase the probability of integration near transcriptionally active cellular promoters.(4,33) Since LMO2 is expressed in HSCs, this locus is susceptible to vector integration.”
MethodHargrove, P. W., Kepes, S., Hanawa, H., Obenauer, J. C., Pei, D., Cheng, C., Gray, J. T., Neale, G., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300394 · Cited by 110
Lentiviral-mediated delivery of siRNAs for antiviral therapy
Morris, K. V., & Rossi, J. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302688 · Cited by 117
“44 In addition, lentiviral based vectors are capable of transducing nondividing cells 45 and specifically targeting the nucleus.”
BackgroundVandegraaff, N., Devroe, E., Turlure, F., Silver, P. A., & Engelman, A. (2006) · Virology · doi:10.1016/j.virol.2005.11.022 · Cited by 106
“Recent evidence that HIV-1 preferentially integrates into actively transcribed genes (Mitchell et al., 2004; Schroder et al., 2002; Wu et al., 2003) has fuelled speculation that components of the PIC may also play a role in directing the virus to active transcription units during integration.”
BackgroundLEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes
Singh, P. K., Plumb, M. R., Ferris, A. L., Iben, J. R., Wu, X., Fadel, H. J., Luke, B. T., Esnault, C., Poeschla, E. M., Hughes, S. H., et al. (2015) · Genes & Development · doi:10.1101/gad.267609.115 · Cited by 109
“The γ retroviruses have a strong preference for integrating near-active enhancers (Wu et al. 2003; De Rijck et al. Corresponding author: henry_levin@nih.gov Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.267609.”
BackgroundInfluentialSelf-citationEfficient genome-wide mutagenesis of zebrafish genes by retroviral insertions
Wang, D., Jao, L.-E., Zheng, N.-Z., Dolan, K. T., Ivey, J., Zonies, S., Wu, X., Wu, K.-M., Yang, H., Meng, Q., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705502104 · Cited by 109
Self-citationSynthetic biology advances and applications in the biotechnology industry: a perspective
Katz, L., Chen, Y. Y., González, R., Peterson, T. C., Zhao, H., & Baltz, R. H. (2018) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-018-2056-y · Cited by 119
“However, retroviral vectors also have a well-established preference for integration at transcription start sites (TSSs) [129], leading to insertional mutagenesis and oncogene activations that have resulted in unanticipated clinical outcomes in multiple gene therapy trials [52, 67].”
BackgroundHuang, X., Wilber, A. C., Bao, L., Tuong, D. T., Tolar, J., Orchard, P. J., Levine, B. L., June, C. H., McIvor, R. S., Blazar, B. R., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2133 · Cited by 109
Genome-wide mapping of foamy virus vector integrations into a human cell line
Nowrouzi, A., Dittrich, M., Klanke, C., Heinkelein, M., Rammling, M., Dandekar, T., von Kalle, C., & Rethwilm, A. (2006) · Journal of General Virology · doi:10.1099/vir.0.81554-0 · Cited by 102
“Consistent with previous studies, HIV integrants avoid the first two segments (Mitchell et al., 2004; Wu et al., 2003).”
BackgroundMethodResultInfluentialHuman artificial chromosomes for gene delivery and the development of animal models
Kazuki, Y., & Oshimura, M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.136 · Cited by 108
Hickman, A. B., Ronning, D. R., Perez, Z. N., Kotin, R. M., & Dyda, F. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00023-1 · Cited by 109
“tion is not dependent on target sequence, in vivo, retroviruses, such as HIV and murine leukemia virus, integrate preferentially into active genes (Schröder et al., 2002; Wu et al., 2003), introducing the possibility of insertional mutagenesis.”
BackgroundHüser, D., Gogol-Döring, A., Lutter, T., Weger, S., Winter, K., Hammer, E.-M., Cathomen, T., Reinert, K., & Heilbronn, R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000985 · Cited by 101
“Linker-Selection-Mediated (LSM) PCR A linker-based strategy described in [39,40] and outlined in more detail in the manual of the GenomeWalker kit (Clontech) was modified as outlined in Figure 1B.”
MethodJadlowsky, J. K., Wong, J. Y., Graham, A. C., Dobrowolski, C., Devor, R. L., Adams, M. D., Fujinaga, K., & Karn, J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01013-13 · Cited by 105
State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 106
“Studies have now shown that both gamma-retroviruses and lentiviruses preferentially integrate in transcriptionally active genes [ 24- 29 ].”
BackgroundRetroviral Integrations in Gene Therapy Trials
Biasco, L., Baricordi, C., & Aiuti, A. (2012) · Molecular Therapy · doi:10.1038/mt.2011.289 · Cited by 106
Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
Burnett, J., Lim, K., Calafi, A., Rossi, J. J., Schaffer, D. V., & Arkin, A. P. (2010) · Journal of Virology · doi:10.1128/jvi.00161-10 · Cited by 116
“identifying human immune deficiency virus (HIV-1) integration sites (95).”
BackgroundKim, S., Kim, N., Dong, B., Boren, D., Lee, S. A., Das Gupta, J., Gaughan, C., Klein, E. A., Lee, C., Silverman, R. H., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01299-08 · Cited by 105
“Previous results have shown that MLV integration favors CpG islands, whereas HIV-1 disfavors CpG islands, and HTLV-1 has no preference (27, 67, 86, 108).”
BackgroundResultInfluentialToll-like receptor 3 activation selectively reverses HIV latency in microglial cells
Alvarez-Carbonell, D., Garcia-Mesa, Y., Milne, S., Das, B., Dobrowolski, C., Rojas, R., & Karn, J. (2017) · Retrovirology · doi:10.1186/s12977-017-0335-8 · Cited by 99
Intravenous, non-viral RNAi gene therapy of brain cancer
Pardridge, W. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1103 · Cited by 104
“(2004) 4(7) Disregarding the concerns related to immunogenicity [8] and insertional mutagenesis caused by chromosomal integration with viruses such as retrovirus [9] or adeno-associated virus (AAV) [10], viral vectors are not effective in brain cancer after intravenous administration because they do not cross the BBB.”
BackgroundRetrovirus Vectors: Toward the Plentivirus?
Baum, C., Schambach, A., Bohne, J., & Galla, M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.007 · Cited by 104
“HIV and derived vectors tend to integrate into transcribed gene regions [123], whereas MLV shows a preference for integration within a few kilobases upstream of the transcriptional start site [124].”
BackgroundYohn, C. T., Jiang, Z., McGrath, S. D., Hayden, K. E., Khaitovich, P., Johnson, M. E., Eichler, M. Y., McPherson, J. D., Zhao, S., Pääbo, S., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030110 · Cited by 104
Biasco, L., Ambrosi, A., Pellin, D., Bartholomae, C., Brigida, I., Roncarolo, M. G., Di Serio, C., von Kalle, C., Schmidt, M., & Aiuti, A. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201000108 · Cited by 104
“…into the host genome, but it is now well established that the majority of them display a semi-random or a non-random integration profile possibly influencing the fate of transduced cells (Brady et al, 2009; Bushman, 2007; Cattoglio et al, 2007; Ciuffi, 2008; Mitchell et al, 2004; Wu et al, 2003).”
BackgroundMethodInfluentialFelice, B., Cattoglio, C., Cittaro, D., Testa, A., Miccio, A., Ferrari, G., Luzi, L., Recchia, A., & Mavilio, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004571 · Cited by 101
“Integration sites from published datasets [3,19] were re-mapped and annotated according to the same criteria.”
DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer
Wang, G. P., Garrigue, A., Ciuffi, A., Ronen, K., Leipzig, J., Berry, C., Lagresle-Peyrou, C., Benjelloun, F., Hacein-Bey-Abina, S., Fischer, A., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn125 · Cited by 100
“4) Lymphoproliferation LN 3687 (215) 89 (20) 2.”
MethodResultEnhancers Are Major Targets for Murine Leukemia Virus Vector Integration
De Ravin, S. S., Su, L., Theobald, N., Choi, U., Macpherson, J. L., Poidinger, M., Symonds, G., Pond, S. M., Ferris, A. L., Hughes, S. H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00011-14 · Cited by 103
“MLV and MLV-based vectors preferentially integrate near transcription start sites (TSS) (8).”
BackgroundInfluentialSelf-citationFoamy Virus Biology and Its Application for Vector Development
Lindemann, D., & Rethwilm, A. (2011) · Viruses · doi:10.3390/v3050561 · Cited by 95
“transcription start sites than MLV vectors, which preferentially integrate at these locations [125].”
BackgroundRetroviral-Mediated Insertional Mutagenesis in Zebrafish
Amsterdam, A., & Hopkins, N. H. (2004) · Methods in cell biology · doi:10.1016/s0091-679x(04)77001-6 · Cited by 103
“The preference of MoMLV integration for the first-intron is consistent with the results in mouse (Mooslehner et al. 1990, Scherdin et al. 1990) and human tissue culture cells (Wu et al. 2003).”
ResultGillet, N. A., Gutiérrez, G., Rodriguez, S. M., de Brogniez, A., Renotte, N., Alvarez, I., Trono, K., & Willems, L. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003687 · Cited by 96
“In fact, most (if not all) retroviruses target a characteristic weak palindromic consensus nucleotide sequence at the site of integration [26,27] and favor insertion within a particular genomic environment [28–30].”
BackgroundChinen, J., Davis, J., De Ravin, S. S., Hay, B. N., Hsu, A. P., Linton, G. F., Naumann, N., Nomicos, E. Y. H., Silvin, C., Ulrick, J., et al. (2007) · Blood · doi:10.1182/blood-2006-11-058933 · Cited by 99
Wang, H., Jurado, K. A., Wu, X., Shun, M.-C., Li, X., Ferris, A. L., Smith, S. J., Patel, P. A., Fuchs, J. R., Cherepanov, P., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks913 · Cited by 100
“Lentiviruses such as HIV-1 integrate within transcriptionally active genes while the integration of the gammaretrovirus Moloney murine leukemia virus (MLV) favors the promoter regions of genes (6,7).”
BackgroundSelf-citationCellular and molecular mechanisms of HIV-1 integration targeting
Engelman, A., & Singh, P. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2772-5 · Cited by 113
miRNA cassettes in viral vectors: Problems and solutions
Liu, Y. P., & Berkhout, B. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.014 · Cited by 109
Peng, P. D., Cohen, C. J., Yang, S., Hsu, C., Jones, S., Zhao, Y., Zheng, Z., Rosenberg, S. A., & Morgan, R. A. (2009) · Gene Therapy · doi:10.1038/gt.2009.54 · Cited by 100
Reverse Genetic Approaches in Zebrafish
Huang, P., Zhu, Z., Lin, S., & Zhang, B. (2012) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.07.004 · Cited by 109
Mouse Mammary Tumor Virus Integration Site Selection in Human and Mouse Genomes
Faschinger, A., Rouault, F., Sollner, J., Lukas, A., Salmons, B., Günzburg, W. H., & Indik, S. (2008) · Journal of Virology · doi:10.1128/jvi.02098-07 · Cited by 97
“primer complementary to the linker (44).”
BackgroundMethodResultInfluentialNeff, T., Beard, B. C., Peterson, L. J., Anandakumar, P., Thompson, J., & Kiem, H. (2004) · Blood · doi:10.1182/blood-2004-08-3169 · Cited by 99
“Standard LAM-PCR(31,32) was combined with a high-throughput screening method.(30) Briefly, Tas I and Msp I restriction For personal use only.”
MethodChromatin Landscapes of Retroviral and Transposon Integration Profiles
de Jong, J., Akhtar, W., Badhai, J., Rust, A. G., Rad, R., Hilkens, J., Berns, A., van Lohuizen, M., Wessels, L. F. A., & de Ridder, J. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004250 · Cited by 89
“[35,36], as well as Figure S3 which shows singleton MuLV profiles, based on a previously published tumor screen [3,37].”
BackgroundT Cell Receptor Gene Therapy for Cancer
Schmitt, T. M., Ragnarsson, G. B., & Greenberg, P. D. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.146 · Cited by 113
“Retroviruses preferentially integrate near the transcriptional start site of active genes, which can result in insertional mutagenesis with dysregulation of gene expression (Mikkers and Berns, 2003; Wu et al. , 2003).”
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 112
Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11
Shigesada, K., van de Sluis, B., & Liu, P. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207748 · Cited by 108
“Recent studies suggest that murine leukemia retroviruses may have a propensity to insert within genes, especially when nearing the transcription start sites (Wu et al., 2003).”
BackgroundSite-Specific Integration of Functional Transgenes into the Human Genome by Adeno/AAV Hybrid Vectors
Recchia, A., Perani, L., Sartori, D., Olgiati, C., & Mavilio, F. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.003 · Cited by 92
“Gene transfer vectors derived from RNA oncoretroviruses or lentiviruses integrate at high efficiency in the human genome, but in an almost random fashion and with a preference for active genes [1,2].”
Cancer Gene Discovery: Exploiting Insertional Mutagenesis
Ranzani, M., Annunziato, S., Adams, D. J., & Montini, E. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0244 · Cited by 88
“Moreover, γ-retroviruses preferably integrate within transcriptional units and in actively transcribed genes (83-85).”
BackgroundInfluentialDeterminants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 107
Lufino, M. M., Edser, P. A., & Wade-Martins, R. (2008) · Molecular Therapy · doi:10.1038/mt.2008.156 · Cited by 94
Stephen, S. L., Freestone, K., Dunn, S., Twigg, M. W., Homer‐Vanniasinkam, S., Walker, J. H., Wheatcroft, S. B., & Ponnambalam, S. (2010) · International Journal of Hypertension · doi:10.4061/2010/646929 · Cited by 109
“Retroviruses and lentiviruses undergo obligatory integration of the provirus into the host genome as a part of the life cycle, and this may lead to activation or increased expression of nearby host genes [169, 170].”
BackgroundHybrid Lentivirus-transposon Vectors with a Random Integration Profile in Human Cells
Staunstrup, N. H., Moldt, B., Mátés, L., Villesen, P., Jakobsen, M., Ivics, Z., Izsvák, Z., & Mikkelsen, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.10 · Cited by 96
Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16
Modlich, U., Schambach, A., Brugman, M. H., Wicke, D. C., Knoess, S., Li, Z., Maetzig, T., Rudolph, C., Schlegelberger, B., & Baum, C. (2008) · Leukemia · doi:10.1038/leu.2008.118 · Cited by 96
Host factors for retroviral integration site selection
Debyser, Z., Christ, F., Rijck, J. D., & Gijsbers, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.12.001 · Cited by 102
A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners
Ding, Z., Liang, J., Lu, Y., Yu, Q., Songyang, Z., Lin, S., & Mills, G. B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606917103 · Cited by 103
Osborn, M. J., McElmurry, R. T., Lees, C. J., DeFeo, A. P., Chen, Z.-Y., Kay, M. A., Naldini, L., Freeman, G. J., Tolar, J., & Blazar, B. R. (2010) · Molecular Therapy · doi:10.1038/mt.2010.249 · Cited by 103
Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors
Izsvák, Z. (2009) · Methods · doi:10.1016/j.ymeth.2009.07.001 · Cited by 95
Walisko, O., Schorn, A. J., Rolfs, F., Devaraj, A., Miskey, C., Izsvák, Z., & Ivics, Z. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300366 · Cited by 106
“[13,14] Indeed, the development of leukaemia in patients treated for X-linked severe combined immunodeficiency is attributed to vector insertions into or near the known proto-oncogene LMO2 , [15] which has led to a temporary interruption of gene therapy trials for the treatment of X-linked severe…”
BackgroundChromosomal Integration of Adenoviral Vector DNA In Vivo
Stephen, S. L., Montini, E., Sivanandam, V. G., Al-Dhalimy, M., Kestler, H. A., Finegold, M. J., Grompe, M., & Kochanek, S. (2010) · Journal of Virology · doi:10.1128/jvi.00751-10 · Cited by 105
“Detailed information on genotoxicity following gene transfer is available for vectors derived from viruses of the Retroviridae and Parvoviridae families (2, 20, 23, 26, 46).”
BackgroundRahrmann, E. P., Collier, L. S., Knutson, T. P., Doyal, M. E., Kuslak, S. L., Green, L. E., Malinowski, R. L., Roethe, L., Akagi, K., Waknitz, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3901 · Cited by 106
“B, when initial attempts to isolate transposon-genomic DNA junctions from laser captured proliferating prostatic lesions failed, the limitations of published linker mediated PCR protocols for cloning transposon-genomic DNA junctions (4, 5, 50) were evaluated using serial dilutions of genomic DNA isolated from two mice…”
Barr, S. D., Ciuffi, A., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.012 · Cited by 89
“Six days after infection, we purified genomic DNA and cloned junctions between human and HIV-vector DNA using ligation-mediated PCR as described previously [5,6,9].”
BackgroundMethodKustikova, O. S., Geiger, H., Li, Z., Brugman, M. H., Chambers, S. M., Shaw, C. A., Pike-Overzet, K., Ridder, D. D., Staal, F. J. T., Keudell, G. V., et al. (2007) · Blood · doi:10.1182/blood-2006-08-044156 · Cited by 95
Kiem, H.-P., Sellers, S., Thomasson, B., Morris, J. C., Tisdale, J. F., Horn, P. A., Hematti, P., Adler, R., Kuramoto, K., Calmels, B., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.006 · Cited by 92
Chang, A. H., & Sadelain, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300060 · Cited by 88
Tan, W., Dong, Z., Wilkinson, T. A., Barbas, C. F., & Chow, S. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1939-1948.2006 · Cited by 89
“The frequency of use of specific sites varies considerably, with some sites being preferred up to several hundred times more than random (54, 61, 62).”
BackgroundLaufs, S., Nagy, K. Z., Giordano, F. A., Hotz‐Wagenblatt, A., Zeller, W. J., & Früehauf, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.001 · Cited by 90
“Our results with this clinically relevant PBPC target population correspond to recently published studies of cell lines that retroviral vector integrations preferentially occur near the transcription start regions of genes [22,23].”
BackgroundMethodResultInfluentialCorrection of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer
Pike‐Overzet, K., Rodijk, M., Ng, Y.-Y., Baert, M. R. M., Lagresle‐Peyrou, C., Schambach, A., Zhang, F., Hoeben, R. C., Hacein‐Bey‐Abina, S., Lankester, A. C., et al. (2011) · Leukemia · doi:10.1038/leu.2011.106 · Cited by 99
“26 In vitro studies have shown that, compared with γ-retroviral vectors, lentiviral vectors have a more favorable integration pattern”
BackgroundINSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions
Berry, C. C., Nobles, C., Six, E., Wu, Y., Malani, N., Sherman, E., Dryga, A., Everett, J. K., Male, F., Bailey, A., et al. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.11.003 · Cited by 85
“However, the gammaretroviruses favor integration near transcription start sites, 10 and H2AZ and H3K4me3 were positively associated, and RNA polymerase II (Pol II) more strongly than for lentiviruses.”
BackgroundImmunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 89
Barr, S. D., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. D. (2005) · Journal of Virology · doi:10.1128/jvi.79.18.12035-12044.2005 · Cited by 86
“Cloning of integration sites was carried out using ligationmediated PCR (26, 31).”
BackgroundMethodInfluentialTalluri, T. R., Kumar, D., Glage, S., Garrels, W., Ivics, Z., Debowski, K., Behr, R., Niemann, H., & Kues, W. A. (2015) · Cellular Reprogramming · doi:10.1089/cell.2014.0080 · Cited by 89
“, 2006), the preferential integration in 5¢-regions (UTRs) of genes that in turn may be associated with insertional mutagenesis (Thomas et al., 2003; Wu et al., 2003; Wu et al., 2006), the limited cargo capacity (Thomas et al.”
BackgroundViolot, S., Hong, S. S., Rakotobe, D., Petit, C., Gay, B., Moreau, K., Billaud, G., Priet, S., Sire, J., Schwartz, O., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.23.12507-12522.2003 · Cited by 80
Carbonaro, D. A., Zhang, L., Jin, X., Montiel-Equihua, C., Geiger, S., Carmo, M., Cooper, A., Fairbanks, L., Kaufman, M. L., Sebire, N. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.265 · Cited by 78
Peterson-Burch, B. D., Nettleton, D. S., & Voytas, D. F. (2004) · Genome biology · doi:10.1186/gb-2004-5-10-r78 · Cited by 95
“Retroviruses also insert preferentially into transcribed regions, with some retroviruses favoring insertions into promoter regions [4,43].”
BackgroundPfeifer, A. (2004) · Transgenic Research · doi:10.1007/s11248-004-2735-5 · Cited by 97
Studamire, B., & Goff, S. P. (2008) · Retrovirology · doi:10.1186/1742-4690-5-48 · Cited by 79
“As different retroviruses appear to favor different integration target sites, a preference for specific host factors as chromatin tethers or for targeting the viral genome to specific sites may be influenced by target site preferences specific to the virus [86,87].”
Interactions between Retroviruses and the Host Cell Genome
Poletti, V., & Mavilio, F. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.10.001 · Cited by 93
“5 kb upstream or downstream of the +1 position of target genes.(4,15,16,65) Thus, gene promoters were considered for some time as the major target of MLV integration.”
BackgroundHIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins.
Maele, B. V., & Debyser, Z. (2005) · PubMed · Cited by 107
Lu, T., Jackson, M. W., Singhi, A. D., Kandel, E., Yang, M., Zhang, Y., Gudkov, A. V., & Stark, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908560106 · Cited by 91
“MLV preferentially targets promoter regions, which may explain the tendency of MLV-based insertional mutagenesis to tag oncogenes rather than tumor suppressors, as the promoter insertion products created by MLV will favor over-expression of full-length or nearly full-length proteins (15, 16).”
BackgroundpiggyBac transposon mediated transgenesis of the human blood fluke, Schistosoma mansoni
Morales, M. E., Mann, V. H., Kines, K. J., Gobert, G. N., Fraser, M. J., Kalinna, B. H., Correnti, J., Pearce, E. J., & Brindley, P. J. (2007) · The FASEB Journal · doi:10.1096/fj.07-8726com · Cited by 92
“Likewise, anchored PCR procedures such as linkermediated PCR have been used to locate exogenous transgenes (59, 60 ).”
MethodCrowe, B. L., Larue, R. C., Yuan, C., Hess, S., Kvaratskhelia, M., & Foster, M. P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516813113 · Cited by 83
Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors
Herrera-Carrillo, E., Liu, Y. P., & Berkhout, B. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.036 · Cited by 86
Integration target site selection for retroviruses and transposable elements
Wu, X., & Burgess, S. M. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4206-9 · Cited by 95
Self-citationHIV-1 inactivation by nucleic acid aptamers
Daniel, M. H. (2006) · Frontiers in bioscience · doi:10.2741/1782 · Cited by 96
“Integrase HIV-1 integrase (IN), the third of the polencoded enzymes, catalyzes the insertion of a doublestranded DNA copy of the viral genome into preferred locations within actively transcribed genes in the host chromosome (95, 96).”
BackgroundMaruggi, G., Porcellini, S., Facchini, G., Perna, S. K., Cattoglio, C., Sartori, D., Ambrosi, A., Schambach, A., Baum, C., Bonini, C., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.51 · Cited by 79
Beard, B. C., Keyser, K. A., Trobridge, G. D., Peterson, L. J., Miller, D. G., Jacobs, M., Kaul, R., & Kiem, H.-P. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.011 · Cited by 81
“Standard LAM-PCR (Schmidt et al ., 2002) was combined with a high-throughput screening method (Wu et al ., 2003).”
InfluentialHoelters, J., Karow, M., Drechsel, M., Geißler, C., Gülkan, H., Böcker, W., Schieker, M., Jochum, M., & Neth, P. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.731 · Cited by 91
“In addition, it has been reported that retroviral vectors exhibit hot spots for integration in actively transcribed genes of the transduced target cells [29], resulting in insertional mutagenesis [30–33].”
BackgroundHematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2012) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 54
The forces driving clonal expansion of the HIV-1 latent reservoir
Liu, R., Simonetti, F. R., & Ho, Y. (2020) · Virology Journal · doi:10.1186/s12985-019-1276-8 · Cited by 93
“Such Moloney murine leukemia virus (MLV)-based gene therapy induces leukemia in treated patients, likely due to MLV preferentially integrating into the transcription start sites [90].”
BackgroundStructure-based prediction of insertion-site preferences of transposons into chromosomes
Geurts, A. M., Hackett, C. S., Bell, J. B., Bergemann, T. L., Collier, L. S., Carlson, C. M., Largaespada, D. A., & Hackett, P. B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl301 · Cited by 80
Shun, M.-C., Botbol, Y., Li, X., Di Nunzio, F., Daigle, J. E., Yan, N., Lieberman, J., Lavigne, M., & Engelman, A. (2008) · Journal of Virology · doi:10.1128/jvi.01561-08 · Cited by 78
“Moloney murine leukemia virus, a -retrovirus, more modestly favors genes and transcriptional activity but in stark contrast to lentiviruses displays a marked preference for promoter regions and associated CpG islands (19, 37, 67 ).”
Retroviral integration site selection
Desfarges, S., & Ciuffi, A. (2010) · Viruses · doi:10.3390/v2010111 · Cited by 78
“showed that murine leukemia virus (MLV) had distinct preferences, favoring integration at transcription start sites and CpG islands [60].”
BackgroundInfluentialGuercio, M., Manni, S., Boffa, I., Caruso, S., Cecca, S. D., Sinibaldi, M., Abbaszadeh, Z., Camera, A., Ciccone, R., Polito, V. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755639 · Cited by 78
Davé, U. P., Akagi, K., Tripathi, R., Cleveland, S. M., Thompson, M. A., Yi, M., Stephens, R., Downing, J. R., Jenkins, N. A., & Copeland, N. G. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000491 · Cited by 78
“Large-Scale Cloning and Sequencing of Viral Integration Sites To identify genes that might cooperate with Lmo2 in tumor induction we adapted an LM-PCR method to amplify the other viral insertions present in the five AKXD leukemias [8,15].”
BackgroundMethodLarge-Scale Production Means for the Manufacturing of Lentiviral Vectors
Schweizer, M., & Merten, O.-W. (2010) · Current Gene Therapy · doi:10.2174/156652310793797748 · Cited by 83
Doi, K., Wu, X., Taniguchi, Y., Yasunaga, J.-I., Satou, Y., Okayama, A., Nosaka, K., & Matsuoka, M. (2005) · Blood · doi:10.1182/blood-2004-11-4350 · Cited by 76
“We determined the genomic sequences adjacent to the HTLV-I provirus integration sites in ATL cells (59 cases) and HTLV-I– infected cells (56 sites) in the 16 carriers by inverse PCR, and then analyzed (1) chromosomal locations, (2) the genes containing integration sites or neighboring genes, (3) the relation of transc…”
MethodSelf-citationNon-Integrating Lentiviral Vectors
Sarkis, C., Philippe, S., Mallet, J., & Serguera, C. (2008) · Current Gene Therapy · doi:10.2174/156652308786848012 · Cited by 74
“This view evolved after the human and mouse genomes were sequenced, allowing integration sites to be accurately mapped; it was then found that lentiviruses and lentiviralderived vectors integrate preferentially into transcriptionally active genes [18-22], Murine Leukemia Virus (MLV) integrates mainly into promoter reg…”
Backgroundp12 Tethers the Murine Leukemia Virus Pre-integration Complex to Mitotic Chromosomes
Elis, E., Ehrlich, M., Prizan-Ravid, A., Laham-Karam, N., & Bacharach, E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003103 · Cited by 76
“The notion of different tethering mechanisms of HIV and MLV is further supported by their differences in integration site selection [42,43,44,45,46], by similarity in the target site selection of a HIV chimeric virus expressing the MLV IN with MLV, and by the increased similarity upon replacement of the HIV Gag of thi…”
Method
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.